Top

Published in:

01-12-2014 | Myelodysplastic Syndromes (M Sekeres, Section Editor)

Lessons from the Atomic Bomb About Secondary MDS

Authors: Tomoko Hata, Daisuke Imanishi, Yasushi Miyazaki

Published in: Current Hematologic Malignancy Reports | Issue 4/2014

Abstract

Myelodysplastic syndromes (MDSs) is a hematological neoplasm defined by ineffective hematopoiesis, dysplasia of hematopoietic cells, and risk of progression to acute leukemia. MDS occurs as de novo or secondary, and chemoradiotherapy for cancers is thought to increase the risk of MDS among patients. Recently, an epidemiological study for MDS among A-bomb survivors was performed, and it clearly demonstrated that the exposure to external radiation significantly increased the risk of MDS. Precise epidemiological data among survivors have revealed important clinical factors related to the risk of leukemias. In this review, by comparing data for secondary MDS and leukemia/MDS among survivors, several factors which would affect the risk of MDS, especially secondary MDS, are discussed.

Ozasa K, Shimizu Y, Suyama A, Kasagi F, Soda M, Grant EJ, et al. Studies of the mortality of atomic bomb survivors, report 14, 1950–2003: an overview of cancer and noncancer diseases. Radiat Res. 2012;177:229–43.PubMedCrossRef

Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res. 1994;137(Suppl):S68–97.PubMedCrossRef

3.••

Hsu WL, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950–2001. Radiat Res. 2013;179(3):361–82. This is an updated data for hematological malignancies among A-bomb survivors in LSS cohort, which demonstrated significantly increased risk for leukemia even 50 years after the bombing.PubMedCrossRef

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189–99.PubMedCrossRef

Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383(9936):2239–52.PubMedCrossRef

Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol. 2003;21(5):897–906.PubMedCrossRef

Kaplan HG, Malmgren JA, Atwood MK. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990–2005. BMC Cancer. 2011;11:260. doi:10.1186/1471-2407-11-260.PubMedCentralPubMedCrossRef

Finch SC. Myelodysplasia and radiation. Radiat Res. 2004;161(5):603–6.PubMedCrossRef

9.••

Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T, et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29(4):428–34. In this report, increased risk for MDS was shown among A-bomb survivors. In this analysis, the authors used two different cohorts: LSS-Nagasaki data and that from Nagasaki University.PubMedCrossRef

10.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.PubMedCrossRef

11.

Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 1994;12(12):2535–42.PubMed

12.

Mukherjee S, Reddy CA, Ciezki JP, Abdel-Wahab M, Tiu RV, Copelan E, et al. Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst. 2014;106(3):djt462. doi:10.1093/jnci/djt462.PubMedCrossRef

13.

Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007;168(1):1–64.PubMedCrossRef

14.•

Ojha RP, Fischbach LA, Zhou Y, Felini MJ, Singh KP, Thertulien R. Acute myeloid leukemia incidence following radiation therapy for localized or locally advanced prostate adenocarcinoma. Cancer Epi. 2010;34:274–8. This paper demonstrated increased risk of leukemia among prostate cancer patients that were treated with radiation than those with operation, showing risk of medical radiation for leukemia.CrossRef

15.

Mauritzson N, Albin M, Rylander L, Billstro R, Ahlgren T, Mikoczy Z, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5,098 unselected cases reported in the literature 1974–2001. Leukemia. 2002;16:2366–78.PubMedCrossRef

16.

Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43–52.PubMedCrossRef

17.

Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol. 2012;30:2340–7.PubMedCrossRef

18.

Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014. doi:10.1200/JCO.2013.52.3381.PubMed

Title: Lessons from the Atomic Bomb About Secondary MDS
Authors: Tomoko Hata
Daisuke Imanishi
Yasushi Miyazaki
Publication date: 01-12-2014
Publisher: Springer US
Published in: Current Hematologic Malignancy Reports / Issue 4/2014
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-014-0235-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

An Immune Dysregulation in MPN

I Walk the Line: How to Tell MDS From Other Bone Marrow Failure Conditions

Back to Biology: New Insights on Inheritance in Myeloproliferative Disorders

Quality of Life in MPN Comes of Age as a Therapeutic Target

Epidemiology of MPN: What Do We Know?

Chronic Myelomonocytic Leukemia Prognostic Classification and Management: Evidence Base and Current Practice

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials